QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: dmd.104.002709v1 33/3/303    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Klees, T. M. Articles by Kharasch, E. D. Search for Related Content PubMed PubMed Citation Articles by Klees, T. M. Articles by Kharasch, E. D.

METABOLISM OF ALFENTANIL BY CYTOCHROME P4503A (CYP3A) ENZYMES

Department of Circulation and Medical Imaging, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway (T.M.K., O.D.); and Department of Anesthesiology (P.S., E.D.K.) and Department of Medicinal Chemistry (E.D.K.), University of Washington, Seattle, Washington

The synthetic opioid alfentanil is an analgesic and an in vivo probe for hepatic and first-pass CYP3A activity. Alfentanil is a particularly useful CYP3A probe because pupil diameter change is a surrogate for plasma concentrations, thereby affording noninvasive assessment of CYP3A. Alfentanil undergoes extensive CYP3A4 metabolism via two major pathways, forming noralfentanil and N-phenylpropionamide. This investigation evaluated alfentanil metabolism in vitro to noralfentanil and N-phenylpropionamide, by expressed CYP3A5 and CYP3A7 in addition to CYP3A4, with and without coexpressed or exogenous cytochrome b₅. Effects of the CYP3A inhibitors troleandomycin and ketoconazole were also determined. Rates of noralfentanil and N-phenylpropionamide formation by CYP3A4 and 3A5 in the absence of b₅ were generally equivalent, although the metabolite formation ratio differed, whereas those by CYP3A7 were substantially less. CYP3A4 and 3A5 were equipotently inhibited by troleandomycin, whereas ketoconazole was an order of magnitude more potent toward CYP3A4. Cytochrome b₅ qualitatively and quantitatively altered alfentanil metabolism, with b₅ coexpression having a greater effect than exogenous addition. Addition or coexpression of b₅ markedly stimulated the formation of both metabolites and changed the formation of noralfentanil but not N-phenylpropionamide from apparent single-site to multisite Michaelis-Menten kinetics. These results demonstrate that alfentanil is a substrate for CYP3A5 in addition to CYP3A4, and the effects of the CYP3A inhibitors troleandomycin and ketoconazole are CYP3A enzyme-selective. Alfentanil is one of the few CYP3A substrates that is metabolized in vitro as avidly by both CYP3A4 and 3A5. Polymorphic CYP3A5 expression may contribute to inter-individual variability in alfentanil metabolism.

This article has been cited by other articles:

				G. V. Bakken, I. Rudberg, H. Christensen, E. Molden, H. Refsum, and M. Hermann Metabolism of Quetiapine by CYP3A4 and CYP3A5 in Presence or Absence of Cytochrome B5 Drug Metab. Dispos., February 1, 2009; 37(2): 254 - 258. [Abstract] [Full Text] [PDF]

				L. T. Newsome, R. S. Weller, J. C. Gerancher, M. A. Kutcher, and R. L. Royster Coronary Artery Stents: II. Perioperative Considerations and Management Anesth. Analg., August 1, 2008; 107(2): 570 - 590. [Abstract] [Full Text] [PDF]

				B. Ma, S. L. Polsky-Fisher, S. Vickers, D. Cui, and A. D. Rodrigues Cytochrome P450 3A-Dependent Metabolism of a Potent and Selective {gamma}-Aminobutyric AcidA{alpha}2/3 Receptor Agonist in Vitro: Involvement of Cytochrome P450 3A5 Displaying Biphasic Kinetics Drug Metab. Dispos., August 1, 2007; 35(8): 1301 - 1307. [Abstract] [Full Text] [PDF]

				R. E. Pearce, J. S. Leeder, and G. L. Kearns BIOTRANSFORMATION OF FLUTICASONE: IN VITRO CHARACTERIZATION Drug Metab. Dispos., June 1, 2006; 34(6): 1035 - 1040. [Abstract] [Full Text] [PDF]

				N. Baririan, Y. Horsmans, J.-P. Desager, R. Verbeeck, R. Vanbinst, P. Wallemacq, and L. Van Obbergh Alfentanil-Induced Miosis Clearance as a Liver CYP3A4 and 3A5 Activity Measure in Healthy Volunteers: Improvement of Experimental Conditions J. Clin. Pharmacol., December 1, 2005; 45(12): 1434 - 1441. [Abstract] [Full Text] [PDF]

				L. K. Kamdem, F. Streit, U. M. Zanger, J. Brockmoller, M. Oellerich, V. W. Armstrong, and L. Wojnowski Contribution of CYP3A5 to the in Vitro Hepatic Clearance of Tacrolimus Clin. Chem., August 1, 2005; 51(8): 1374 - 1381. [Abstract] [Full Text] [PDF]